Avant Technologies and Ainnova Advancing Proprietary Retinal Camera to Market With Vision AI Software
Avant Technologies (OTCQB: AVAI) and Ainnova Tech announced plans to advance a proprietary low-cost retinal camera integrated with Ainnova's Vision AI software platform. The combined technology will provide retinal scans for early disease detection, including diabetic retinopathy, glaucoma, macular edema, and other conditions. The system will be marketed as a Software as a Service (SaaS) + retinal camera package through Ai-nova Acquisition Corp (AAC), targeting primary care clinics, insurance companies, opticians, and pharmacies with a pay-per-use model. AAC holds licensing rights for North America and Europe.
Avant Technologies (OTCQB: AVAI) e Ainnova Tech hanno annunciato piani per sviluppare una fotocamera retinica proprietaria a basso costo integrata con la piattaforma software Vision AI di Ainnova. La tecnologia combinata fornirà scansioni retiniche per la rilevazione precoce di malattie, inclusa la retinopatia diabetica, il glaucoma, l'edema maculare e altre condizioni. Il sistema sarà commercializzato come un pacchetto Software as a Service (SaaS) + fotocamera retinica attraverso Ai-nova Acquisition Corp (AAC), mirato a cliniche di cure primarie, compagnie assicurative, ottici e farmacie con un modello di pagamento per utilizzo. AAC detiene i diritti di licenza per il Nord America e l'Europa.
Avant Technologies (OTCQB: AVAI) y Ainnova Tech anunciaron planes para avanzar en una cámara retinal propietaria de bajo costo integrada con la plataforma de software Vision AI de Ainnova. La tecnología combinada proporcionará escaneos retinianos para la detección temprana de enfermedades, incluida la retinopatía diabética, el glaucoma, el edema macular y otras condiciones. El sistema será comercializado como un paquete de Software como Servicio (SaaS) + cámara retinal a través de Ai-nova Acquisition Corp (AAC), dirigido a clínicas de atención primaria, compañías de seguros, ópticos y farmacias con un modelo de pago por uso. AAC posee los derechos de licencia para América del Norte y Europa.
Avant Technologies (OTCQB: AVAI)와 Ainnova Tech는 Ainnova의 Vision AI 소프트웨어 플랫폼과 통합된 저비용 저작권 소유 망막 카메라를 발전시키기 위한 계획을 발표했습니다. 결합된 기술은 당뇨병성 망막병증, 녹내장, 황반부종 및 기타 질환을 포함한 조기 질병 탐지를 위한 망막 스캔을 제공합니다. 이 시스템은 Ai-nova Acquisition Corp (AAC)를 통해 서비스형 소프트웨어(SaaS) + 망막 카메라 패키지로 마케팅될 예정이며, 1차 진료 클리닉, 보험 회사, 안경사 및 약국을 대상으로 사용량 기반의 지급 모델을 제공합니다. AAC는 북미와 유럽에 대한 라이선스 권리를 보유하고 있습니다.
Avant Technologies (OTCQB: AVAI) et Ainnova Tech ont annoncé des projets pour développer une caméra rétinienne propriétaire à faible coût intégrée à la plateforme logicielle Vision AI d'Ainnova. La technologie combinée fournira des scans rétiniens pour la détection précoce de maladies, y compris la rétinopathie diabétique, le glaucome, l'œdème maculaire et d'autres conditions. Le système sera commercialisé en tant que package logiciel en tant que service (SaaS) + caméra rétinienne via Ai-nova Acquisition Corp (AAC), ciblant les cliniques de soins primaires, les compagnies d'assurance, les opticiens et les pharmacies avec un modèle de paiement à l'utilisation. AAC détient les droits de licence pour l'Amérique du Nord et l'Europe.
Avant Technologies (OTCQB: AVAI) und Ainnova Tech haben Pläne angekündigt, eine proprietäre kostengünstige Netzhautkamera zu entwickeln, die mit der Vision AI-Softwareplattform von Ainnova integriert ist. Die kombinierte Technologie wird Netzhautscans zur frühzeitigen Erkennung von Krankheiten bereitstellen, darunter diabetische retinopathie, Glaukom, Makulaödem und andere Erkrankungen. Das System wird als Software-as-a-Service (SaaS) + Netzhautkamerapaket über die Ai-nova Acquisition Corp (AAC) vermarktet, wobei Zielgruppen primäre Gesundheitskliniken, Versicherungsunternehmen, Optiker und Apotheken mit einem Pay-per-Use-Modell sind. AAC hat die Lizenzrechte für Nordamerika und Europa.
- Development of low-cost retinal camera to reduce market entry barriers
- Pay-per-use SaaS business model offering recurring revenue potential
- Existing commercial agreements with pharmaceutical companies, clinics, and insurance providers
- Exclusive licensing rights for North American and European markets
- Product still in development phase with no clear timeline for market launch
- Pending regulatory approvals and compliance requirements
- Distribution agreements still under negotiation
LAS VEGAS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and its partner Ainnova Tech, Inc. (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies will advance Ainnova’s proprietary low-cost retinal camera, which will be used for fundus photography, and seamlessly packaged together with Ainnova’s Vision AI software platform for commercialization. By combining the two technologies, Ainnova’s versatile camera will provide precise retinal scans to its AI software leading to even more accurate data.
Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova will integrate into the software like the detection of kidney disease, liver fat, cardiovascular risk, and pre-diabetes.
Currently, Ainnova’s Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera that captures retinal images automatically and then uploads those images to the Vision AI software platform, which then produces a “risk report” in mere seconds. Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova’s technology portfolio. AAC owns the licensing rights to develop, maintain, and market Ainnova’s technology portfolio in both North America (United States and Canada) and throughout Europe.
Vinicio Vargas, Chief Executive Officer of Ainnova and member of AAC’s Board of Directors, said, “The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera should allow us to not only enter the market, but to capture a large share of the market. To that end, I will be meeting with a leading U.S. provider of digital healthcare solutions to discuss a potential distribution agreement, investment, and regulatory support.”
AAC will market the two technologies as a Software as a Service (SaaS) + retinal camera package with the hope of making retinal scans a part of routine healthcare. The business model is a pay-per-use platform, per patient, monthly, aimed at primary care clinics, insurance companies, opticians, pharmacies, occupational health companies that provide the service to employees of many companies, and pharmaceutical companies that sell the treatments or therapies.
Vinicio Vargas added, “Our vision is that the retina will be a new standard in primary care, as basic as taking a patient’s blood pressure, and together with other datapoints, such as demographic data or laboratory results, to generate a complete report of preventive medicine.
“The goal is to provide patients with a risk screening so that they can be referred to the appropriate specialist. Our proprietary retinal camera, combined with our VisionAI software technology will offer a real accessible opportunity for early detection - and this is how we are going to impact the world.”
Ainnova currently has commercial agreements with pharmaceutical companies, clinics, insurance companies, and medical service providers, and these relationships should offer AAC guidance into marketing the SaaS + retinal camera package in the North American and European markets.
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas, founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies, Inc.
Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies, Inc.
info@avanttechnologies.com
FAQ
What diseases can Avant Technologies' (AVAI) Vision AI platform detect?
How will Avant Technologies (AVAI) market their retinal camera and Vision AI software?
What territories are covered by Avant Technologies' (AVAI) licensing rights?
